Skip to main content
Meds CJC-1295

A clear, browsable digest of the CJC-1295 research literature — every pharmacokinetic study, the DAC vs no-DAC distinction, and where the human data actually stand, laid out like a well-organized listing.

The studies behind each small number

Where can you check each CJC-1295 study?

You can find each study below. A DOI or PubMed number is a lookup number that opens the paper's record. Human studies show blood changes; rat work helps explain the long stay.

Read the human study resultsRead what this site does

Which study supports each result?

Each small number leads to one CJC-1295 study below. The main human results come from Teichman 2006 [1] and Ionescu/Frohman 2006 [3]. Jette 2005 tested the albumin link in rats [2]. Alba 2006 gave the drug each day to mice missing their normal growth message [4]. A 2024/2025 review explains why researchers tried to make related drugs last longer [13].

When the same number appears on several pages, it still points to one study. One example is the 5.8-8.1 day half-life. Another is the 28-day rise in IGF-1, a liver-made hormone tied to growth and repair. The finding of four times as much growth hormone in rats also comes from one study. The full paper names and links are below, where you can open them and check each result.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and potency. (D-Ala2 GHRH analog pharmacology). 1994. ↗
  8. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. ↗
  9. Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men. (Early GRF(1-29) pharmacokinetic study). 1986. ↗
  10. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003. ↗
  11. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers / swine. Pharm Res. 1999. ↗
  12. Modified GRF (1-29) - chemical and pharmacological description (the no-DAC, tetrasubstituted GHRH(1-29) analog distinct from CJC-1295 DAC). Encyclopedic reference. 2024. ↗
  13. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  14. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗
  15. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. ↗
  16. (GH sodium-retention study). GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. ↗
  17. (GHRH analog pulsatility/insulin study). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
  18. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting - briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. ↗
  19. ConjuChem Inc. (trial sponsor). A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov. 2006. ↗
  20. World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA International Standard. 2025. ↗